Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ARDS NASDAQ:CBLI NASDAQ:CMRA NASDAQ:EVLO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDSAridis Pharmaceuticals$0.00+550.0%$0.00$0.00▼$0.05$11K43.7916,251 shs302,510 shsCBLICleveland BioLabs$3.19$1.62▼$10.97$3K0.7271,922 shs11,817 shsCMRAComera Life Sciences$0.00$0.00$0.00▼$0.03$6K1.286,565 shsN/AEVLOEvelo Biosciences$0.00$0.00$0.00▼$0.02$9K0.859,482 shs110 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDSAridis Pharmaceuticals0.00%-60.00%+100.00%+100.00%-98.00%CBLICleveland BioLabs0.00%0.00%-33.33%-33.33%-66.67%CMRAComera Life Sciences0.00%0.00%0.00%0.00%-99.10%EVLOEvelo Biosciences0.00%0.00%0.00%0.00%-97.78%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeARDSAridis Pharmaceuticals$0.00+550.0%$0.00$0.00▼$0.05$11K43.7916,251 shs302,510 shsCBLICleveland BioLabs$3.19$1.62▼$10.97$3K0.7271,922 shs11,817 shsCMRAComera Life Sciences$0.00$0.00$0.00▼$0.03$6K1.286,565 shsN/AEVLOEvelo Biosciences$0.00$0.00$0.00▼$0.02$9K0.859,482 shs110 shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceARDSAridis Pharmaceuticals0.00%-60.00%+100.00%+100.00%-98.00%CBLICleveland BioLabs0.00%0.00%-33.33%-33.33%-66.67%CMRAComera Life Sciences0.00%0.00%0.00%0.00%-99.10%EVLOEvelo Biosciences0.00%0.00%0.00%0.00%-97.78%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceARDSAridis Pharmaceuticals 0.00N/AN/AN/ACBLICleveland BioLabs 0.00N/AN/AN/ACMRAComera Life Sciences 0.00N/AN/AN/AEVLOEvelo Biosciences 0.00N/AN/AN/ACompare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookARDSAridis PharmaceuticalsN/AN/AN/AN/AN/AN/ACBLICleveland BioLabs$260K0.00N/AN/A$0.87 per share0.00CMRAComera Life Sciences$1.00M0.01N/AN/AN/A∞EVLOEvelo BiosciencesN/AN/AN/AN/AN/AN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateARDSAridis Pharmaceuticals-$30.37MN/A0.00∞N/AN/AN/AN/AN/ACBLICleveland BioLabs-$2.40MN/A0.00N/AN/AN/A-32.84%-31.29%N/ACMRAComera Life Sciences-$18MN/A0.00∞N/AN/AN/AN/AN/AEVLOEvelo Biosciences-$114.53MN/A0.00∞N/AN/AN/AN/A11/24/2025 (Estimated)Compare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthARDSAridis PharmaceuticalsN/AN/AN/AN/AN/ACBLICleveland BioLabsN/AN/AN/AN/AN/ACMRAComera Life SciencesN/AN/AN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioARDSAridis PharmaceuticalsN/AN/AN/ACBLICleveland BioLabsN/A45.9345.93CMRAComera Life SciencesN/AN/AN/AEVLOEvelo BiosciencesN/AN/AN/ACompare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipARDSAridis Pharmaceuticals9.65%CBLICleveland BioLabs5.09%CMRAComera Life SciencesN/AEVLOEvelo Biosciences0.31%Insider OwnershipCompanyInsider OwnershipARDSAridis Pharmaceuticals5.50%CBLICleveland BioLabs1.03%CMRAComera Life Sciences8.90%EVLOEvelo Biosciences1.02%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableARDSAridis Pharmaceuticals3053.32 million50.39 millionNot OptionableCBLICleveland BioLabs415.48 millionN/ANot OptionableCMRAComera Life Sciences230.74 million28.00 millionNot OptionableEVLOEvelo Biosciences12018.98 million18.79 millionNo DataCBLI, ARDS, EVLO, and CMRA HeadlinesRecent News About These CompaniesEvelo's Compass E-Trike Has Comfort, Range, and Even Power; Priced Decently Well, TooApril 17, 2025 | autoevolution.comAEvelo Biosciences (OTC:EVLO) Stock Quotes, Forecast and News SummaryOctober 4, 2024 | benzinga.comEvelo Biosciences (OTC:EVLO) Stock, Insider Trading ActivityOctober 4, 2024 | benzinga.comEVLO Expands Portfolio with Launch of EVLO SYNERGY - A High-Density 5 MWh Battery Storage SolutionAugust 30, 2024 | ca.finance.yahoo.comEvelo Biosciences, Inc. (EVLO)August 24, 2024 | nz.finance.yahoo.comEvelo Biosciences Stock (OTC:EVLO), Short Interest ReportFebruary 22, 2024 | benzinga.comEvelo Biosciences: Notice Of Delisting Or Failure To Satisfy A Continued Listing Rule Or Standard; Transfer Of ListingDecember 6, 2023 | cbonds.comCEvelo Biosciences, a microbiome company launched by Flagship, shuts downNovember 24, 2023 | msn.comEvelo Bio Shutdown Follows a Series of Microbiome Therapy Trial FailuresNovember 23, 2023 | medcitynews.comMFlagship-backed startup Evelo, behind failed eczema drug, to dissolveNovember 22, 2023 | bizjournals.comEvelo’s voyage ends, as Flagship-founded biotech finds dissolution is only viable optionNovember 22, 2023 | fiercebiotech.comFFMR LLC Reduces Stake in Evelo Biosciences IncNovember 14, 2023 | finance.yahoo.comEvelo Biosciences Inc EVLONovember 10, 2023 | morningstar.comMPresident & CEO GILL SIMBA sale 1,996 shares of Evelo Biosciences Inc [EVLO]November 3, 2023 | knoxdaily.comKQ3 2023 Horizon Technology Finance Corp Earnings CallNovember 2, 2023 | finance.yahoo.comHorizon Technology Finance Corporation (NASDAQ:HRZN) Q3 2023 Earnings Call TranscriptNovember 2, 2023 | finance.yahoo.comEvelo Biosciences (EVLO) Price Target Increased by 53.85% to 10.20November 1, 2023 | msn.comEVLO shares expected to outperform in the next 12 monthsOctober 26, 2023 | knoxdaily.comKTD Cowen Downgrades Evelo Biosciences (EVLO)October 19, 2023 | msn.comRecent Insider Activity Could Benefit Evelo Biosciences Inc (EVLO)October 18, 2023 | knoxdaily.comKMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025NIO Just Got Its Second Upgrade of the Month, and It’s BigBy Sam Quirke | August 28, 20255 High Short-Interest Stocks to Buy Before NovemberBy Thomas Hughes | August 20, 20253 Plays on Gold in Case Trust in the Fed SlipsBy Nathan Reiff | September 10, 2025CBLI, ARDS, EVLO, and CMRA Company DescriptionsAridis Pharmaceuticals NASDAQ:ARDS$0.0013 +0.00 (+550.00%) As of 01:31 PM EasternAridis Pharmaceuticals, Inc., a late-stage biopharmaceutical company, discovers and develops targeted immunotherapy using fully human monoclonal antibodies (mAb) to treat life-threatening infections. Its lead product candidate is AR-301, a fully human mAb of immunoglobulin 1 (IgG1) that has completed Phase III pivotal trials for the treatment of lung infections resulting from S. aureus alphatoxin, as well as developing AR-301 as an adjunctive therapy with SOC antibiotics to treat hospital acquired pneumonia and ventilator associated pneumonia. The company is also developing AR-320, a fully human IgG1 monoclonal antibody targeting S. aureus alpha toxin to treat infections caused by methicillin-resistant Staphylococcus aureus and methicillin-susceptible S. aureus; AR 501, an inhaled gallium citrate, which is in Phase 1/2a for the treatment of chronic lung infection associated with cystic fibrosis; and AR-101, a human IgM mAb, which is in Phase II clinical trials targeting Pseudomonas aeruginosa liposaccharides serotype O11. In addition, it develops AR-401 that is in preclinical stage to treat infections caused by Acinetobacter baumannii; AR-201, a fully human IgG1 mAb preclinical program for respiratory syncytial virus; and AR-701, a cocktail of two fully human immunoglobulin 1. The company was founded in 2003 and is headquartered in Los Gatos, California.Cleveland BioLabs NASDAQ:CBLICytocom, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of novel small molecule immunotherapies. Its product applies to autoimmune, inflammatory, infectious diseases and cancers. The company was founded by Andrei V. Gudkov and Yakov Kogan on June 5, 2003 and is headquartered in Fort Collins, CO.Comera Life Sciences NASDAQ:CMRA$0.0002 0.00 (0.00%) As of 09/12/2025Comera Life Sciences Holdings, Inc., a preclinical stage life sciences company, develops an internal portfolio of proprietary therapeutics that incorporate its proprietary formulation platform. Its SQore platform is designed to enable the conversion of intravenous biologics to subcutaneous versions. The company's lead pipeline candidate is CLS-001, a subcutaneous formulation of vedolizumab for the treatment of inflammatory bowel disease, including Crohn's disease and ulcerative colitis. Comera Life Sciences Holdings, Inc. was founded in 2014 and is headquartered in Woburn, Massachusetts.Evelo Biosciences NASDAQ:EVLO$0.0005 0.00 (0.00%) As of 09/12/2025Evelo Biosciences, Inc., a clinical-stage biotechnology company, focuses on discovering and developing oral medicines that act on immune cells in the small intestine with systemic effects. It is developing EDP1815, a whole-microbe product candidate, which has completed a Phase 2 trial for the treatment of psoriais; and is in Phase 2 clinical trial for the treatment of atopic dermatitis. The company is also developing EDP1867, a non-live pharmaceutical preparation for single strain of Veillonella parvula, which is in Phase 1b clinical trial; EDP2939, an investigational oral biologic for the potential treatment of inflammatory diseases; and EDP1908, a product candidate for oncology. Evelo Biosciences, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Palantir’s Commercial Growth Story Is Just Getting Started The Applied Digital Breakout Is Only the Beginning $100 Million Buyback in Upwork Stock Follows a Strong Quarter Reddit Hits Record Highs: Why Wall Street Is Taking Notice Royal Caribbean's 33% Dividend Hike Signals Deeper Growth FuelCell Energy's Stock: Is a Fundamental Breakout Underway? After a Strong Wall Street Debut, Klarna's Real Work Begins MarketBeat Week in Review – 09/08 - 09/12 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
